Inovio to assess new T-cell therapy in Phase Ib/II combination trial for bladder cancer

Inovio Pharmaceuticals has signed a clinical collaboration with Roche Group ’s division Genentech to evaluate the combination of its INO-5401 and INO-9012 with atezolizumab (Tecentriq) in a Phase Ib/II clinical trial to treat advanced bladder cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news